Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Beijing Immunochina Raises $15 Million for CAR-T Portfolio

publication date: Oct 20, 2020

Beijing Immunochina Pharma  raised $15 million in C+ round of financing to support its portfolio of 12 CAR-T candidates.  Established in 2015, Beijing Immunochina has developed a serum-free production process and large-scale gene vector production platforms to improve the safety and efficacy of CAR-T products. It has started clinical trials for one CAR-T candidate, IM19, that it is co-developing with China's Simcere Pharma for leukemia and non-Hodgkin's lymphoma. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021